🍄🍁 **SPRC** Pharma Tip that's getting a lot of attention!

Cannabinoid-Pharmaceuticals are Positioned to Take Over the Pharmaceutical Industry! [UNSUBSCRIBE]( NEW TIP: NASDAQ: SPRC Cannabinoid-Pharmaceuticals are Positioned to Take Over the Pharmaceutical Industry and this Company is Paving the Way… Greetings All, For many years cannabinoids have been the biggest buzz topic in wellness… Trading at around $3, one NASDAQ pharma company is revolutionizing cannabinoid-based treatments by developing proprietary pharmaceuticals that increase patients’ safety by reducing doses all while maintaining effectiveness. The company’s robust IP portfolio focused on disorders of the central nervous system, puts the company in very exciting markets that have seen stellar growth in recent years. With strong leadership, recent joint ventures, and an entrance into the booming psychedelics space, the company may not remain under the radar much longer. Especially as a report by Market Digits estimates that the psychedelic sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020! The conversation about psychedelics is getting much louder and it may be opportunistic to keep a close eye on emerging companies that may soon be sitting at the forefront of it. SciSparc Ltd. (NASDAQ: SPRC) has been climbing the ranks of the pharma-industry and is revolutionizing the way the world approaches modern medicine through cannabinoids and psychedelics. SPRC should be at the top of your watch-list as it could be positioned for impressive growth! BREAKING NEWS! SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”). FULL STORY HERE: [Image]( [( SciSparc Ltd. NASDAQ: SPRC Aiming to Become a Leader in the Pharma Industry with a Robust IP Portfolio ALL Focused on Disorders of the Central Nervous System! SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. Led by an experienced team of senior executives and scientists, the company’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. SPRC’s current candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain using cannabinoid pharmaceuticals. SPRC is well-aware of the cannabinoid opportunity in the world of pharmaceuticals and the company is dedicated to developing unique cannabinoid technologies for treatment of central nervous system disorders. The global cannabis pharmaceuticals market size is expected to reach [$127.1 billion by 2028!]( With this focus, SPRC is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): >> SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation. This is the company’s proprietary drug candidate, containing Dronabinol, FDA approved synthetic form of THC, with the endocannabinoid palmitoylethanolamide (PEA). >> SCI-160 for the treatment of pain. >> SCI-210 for the treatment of autism spectrum disorder and status epilepticus. Joint Venture Agreement with MitoCareX Bio Ltd. Not long ago, SPRC announced completion of its previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, with MitoCareX Bio Ltd., an Israeli corporation. MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers’ significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family ( Solute Carrier Family 25, SLC25 ) consists of 53 members and is the largest solute transporter. Details of the JV agreement can be found [HERE.]( Approvals for Phase IIb Clinical Study for SCI-110 in Tourette Syndrom Patients Near the end of the month, SPRC received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome, or TS. The Company is evaluating additional clinical sites to join the Phase 2b trial to expedite patient enrollment in a timely manner. This is a critical step toward the initiation of the company’s Phase IIb trial in TS! [Image]( TS is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. With onset before age 18, about half to two-thirds of TS cases improve during adolescence, while adults are generally more severe patients. Tics may be associated with a premonitory sensation to perform a specific action, which may lead to “relief” once performed. The objective of this Phase IIb randomized, multi-national, multi-center, double-blind, placebo controlled cross-over study is to evaluate the efficacy, safety and tolerability of SPRC’s proprietary drug candidate SCI-110 in adult patients (between 18 and 65 years of age). The launch of the trial is now pending approvals by the Ministry of Health in both countries. Joint Pre-Clinical Trial with Clearmind Medicine Inc. SPRC has revealed positive safety profile results from its joint pre-clinical trial with Clearmind Medicine Inc., (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a psychedelic pharmaceutical company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems. The trial tested the proprietary combination of SPRC’s CannAmide™ with Clearmind's psychedelic molecule, MEAI, for alcohol consumption. [Image]( A histopathology assessment was conducted on several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) from all experiment groups (n=3-5 per group) to determine the safety of the proprietary combination of MEAI and CannAmide™ versus control (mice) that were not exposed to alcohol). The severity of changes was scored by a 5-point scale by a qualified blinded toxicologist (Schafer et al., Toxicol Pathol 2018, 46:256-265). The results indicated a high safety profile of the combination treatment with no treatment-related changes observed! Results showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p<0.01) compared to consumption before treatment. Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg compared to consumption before treatment! This puts the company in another favorable market as a report by [Market Digits estimates]( that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020! A New Add to the Company’s Established Team The company recently appointed Professor Avi Schroeder as a member of the Company's Scientific Advisory Board. Prof. Schroeder will support the development of the Company's top-tier, proprietary, investigational drug candidate SCI-160 program for the treatment of pain. A recipient of over 20 national and international innovation awards as well as the inventor of 14 patents, Professor Schroeder is an exciting addition to SPRC and could help propel the company for even larger growth! "As we continue to make progress in our innovative program to treat pain, utilizing our non-opioid analgesic pain management solution, SCI-160, reinforcing our SAB is essential. Our plans are to commence the Pre-IND process further this year, followed by an FDA Investigational New Drug (IND) Phase I study application for our treatment for pain. We welcome Prof. Schroeder and the great contribution he will bring to our SAB, that already includes a diverse list of renowned researchers, physicians and experts advising the company." - Dr. Adi Zuloff-Shani, CTO In fact, the company’s recent leadership changes positions them for the best possible growth. SPRC is managed by an established team with a proven track record of execution in drug development, working in concert with a world class, award-winning, scientific advisory board chaired by the renowned Professor Raphael Mechoulam. Together they bring decades of experience in biochemistry and pharmacology, research and development, manufacturing, international distribution, clinical and regulatory affairs, as well as financial acumen to the company’s operation. MARKET POTENTIAL - The global Alzheimer’s therapeutics market is projected to reach $13.68 by 2027 from $7.48 in 2019. - The global epilepsy market size would grow from $8.8B in 2018 to $9.5B towards the end of 2023 - The global ASD therapeutics market was approximately $3.3B in 2018 and is expected to reach approximately $4.6B by 2026 - Tourette Syndrome (TS) market was $80M in 2019 and is expected to reach $98.7M by 2023 - The global chronic pain treatment market was valued at $77.8B in 2019 [Image]( While the usage of cannabis has been popular in recent years, it’s only very recently that we are discovering the rarecannabinoid potential. Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies [have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia](. Cannabinoids are inexpensive, as well as natural, which is an exciting contrast to traditional forms of drugs and medicine which often have adverse or addictive consequences. Psychedelics have become an increasingly popular area for medical research and studies. A report by [Market Digits]( that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020! With their exciting and diverse IP portfolio and recent ventures into non-traditional forms of medicine, SciSparc Ltd. (NASDAQ: SPRC) is quickly becoming an exciting specialty pharmaceutical company to keep your eyes on! The company is in multiple exciting collaborations/joint ventures in many up-and-coming areas that proves they have undeniable potential for great market growth! Disclaimer: This Newsletter/Website provides information about the stock market and other investments. This Newsletter/Website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This Newsletter/Website is for informational purposes only. The Author of this Newsletter/Website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Copyright 2022 © [TopStockTips.com]( is 50% owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@TopStockTips.com Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in SPRC. We have been compensated up to Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Awareness Consulting Network for a 3 Day Marketing Program regarding SPRC with a start date of 5/31/2022 to 6/02/2022. TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. 18 R. Frei Tomé de Jesus Lisboa Lisboa 1700 PORTUGAL [Unsubscribe]( | [Change Subscriber Options](